
Pubmed-entry ::= {
  pmid 29889667,
  medent {
    em std {
      year 2018,
      month 6,
      day 12,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "Hormone Therapy: Key Points From NAMS 2017 Position Statement."
      },
      authors {
        names std {
          {
            name ml "Pinkerton JV",
            affil str "University of Virginia Health System, Charlottesville,
 Virginia; The North American Menopause Society, Cleveland, Ohio."
          }
        }
      },
      from journal {
        title {
          iso-jta "Clin Obstet Gynecol",
          ml-jta "Clin Obstet Gynecol",
          issn "1532-5520",
          name "Clinical obstetrics and gynecology"
        },
        imp {
          date std {
            year 2018,
            month 9
          },
          volume "61",
          issue "3",
          pages "447-453",
          language "eng",
          pubstatus ppublish,
          history {
            {
              pubstatus pubmed,
              date std {
                year 2018,
                month 6,
                day 12,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2019,
                month 3,
                day 15,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus other,
              date std {
                year 2018,
                month 6,
                day 12,
                hour 6,
                minute 0
              }
            }
          }
        }
      },
      ids {
        pubmed 29889667,
        doi "10.1097/GRF.0000000000000383",
        other {
          db "ELocationID doi",
          tag str "10.1097/GRF.0000000000000383"
        }
      }
    },
    abstract "The goal of the 2017 North American Menopause Society Hormone
 Therapy (HT) Position Statement is to remove fear about HT and encourage
 individualized shared decision making, using best available evidence.
 Systemic HT is safe and effective for symptomatic menopausal women aged
 younger than 60 years and within 10 years of menopause. Special populations
 of early menopause, high risk for fracture, risk of breast or uterine cancer,
 and extended duration are discussed. With longer duration of use, periodic
 evaluation and reassessment of health risks are needed. Lowered doses,
 transdermal therapies or newer options may enhance the benefit:risk ratio for
 HT.",
    mesh {
      {
        term "Administration, Intravaginal"
      },
      {
        term "Breast Neoplasms",
        qual {
          {
            subh "complications"
          },
          {
            subh "genetics"
          }
        }
      },
      {
        term "Contraindications, Drug"
      },
      {
        term "Endometrial Neoplasms",
        qual {
          {
            subh "complications"
          }
        }
      },
      {
        term "Estrogens",
        qual {
          {
            subh "administration & dosage"
          }
        }
      },
      {
        term "Female"
      },
      {
        term "Genital Diseases, Female",
        qual {
          {
            subh "drug therapy"
          },
          {
            subh "physiopathology"
          }
        }
      },
      {
        mp TRUE,
        term "Hormone Replacement Therapy"
      },
      {
        term "Humans"
      },
      {
        term "Menopause",
        qual {
          {
            mp TRUE,
            subh "physiology"
          }
        }
      },
      {
        term "Practice Guidelines as Topic"
      },
      {
        term "Societies, Medical"
      }
    },
    substance {
      {
        type nameonly,
        name "Estrogens"
      }
    },
    pmid 29889667,
    pub-type {
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    },
    status medline
  }
}


